Barclays Lowers Moderna (NASDAQ:MRNA) Price Target to $111.00

Moderna (NASDAQ:MRNA) had its target price cut by Barclays from $125.00 to $111.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

MRNA has been the subject of a number of other reports. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday. Finally, TD Cowen dropped their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $93.18.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $42.75 on Friday. Moderna has a 12 month low of $42.25 and a 12 month high of $170.47. The firm has a market capitalization of $16.43 billion, a price-to-earnings ratio of -7.35 and a beta of 1.69. The business’s 50 day simple moving average is $61.85 and its 200-day simple moving average is $99.09. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the business posted ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts forecast that Moderna will post -9.89 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 2,930 shares of company stock worth $217,170. Corporate insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna during the 2nd quarter valued at approximately $26,000. Cedar Wealth Management LLC boosted its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the last quarter. Family Firm Inc. bought a new position in Moderna during the 2nd quarter valued at $33,000. Bank & Trust Co acquired a new position in Moderna during the 2nd quarter worth $36,000. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Moderna in the 2nd quarter worth about $48,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.